Iovance Biotherapeutics, Inc. (IOVA) — Stock Score Summary

Iovance Biotherapeutics, Inc. (IOVA) has a MoatMap StockRank of 53/100 based on Quality (32/100), Value (39/100), and Momentum (68/100) factor scores. The current signal is HOLD. Iovance Biotherapeutics is a commercial-stage biotech pioneer in cell therapy. While its product Amtagvi has high demand, Iovance is a cash-burning entity that had to build out its own highly capital-intensive manufacturing facility due to external CDMO bottlenecks, failing our strict Terry Smith and Buffett filters for positive owner earnings.

Iovance Biotherapeutics, Inc. is a pioneer in the development of tumor-infiltrating lymphocyte (TIL) therapies for patients with solid tumor cancers. The company's competitive moat is its first-mover advantage, proprietary manufacturing processes, and FDA approval for Amtagvi, the first cellular therapy for a solid tumor. It operates as a leading-edge biotechnology player in the oncology space.

Key Financial Metrics

Price$3.88
Market Cap$1.9B
P/E (Forward)-13.72
Price/Book2.66
Return on Equity-47.5%
Return on Invested Capital-51.4%
Debt/Equity6.62
Gross Margin39.4%
Operating Margin-113.5%
Revenue Growth44.8%
Free Cash Flow$-149M

Iovance Biotherapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Iovance Biotherapeutics, Inc.’s (IOVA) StockRank?
MoatMap’s StockRank for Iovance Biotherapeutics, Inc. (IOVA) is 53/100, with a Hold signal. It is a composite of Quality (32), Value (39), and Momentum (68) factor ranks across MoatMap’s 19,000+ stock universe.
Does Iovance Biotherapeutics, Inc. have an economic moat?
Iovance Biotherapeutics, Inc. (IOVA) has a Quality factor score of 32/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Iovance Biotherapeutics, Inc. a buy, hold, or sell?
MoatMap’s current signal for Iovance Biotherapeutics, Inc. (IOVA) is Hold, based on a StockRank of 53/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Iovance Biotherapeutics, Inc. in?
Iovance Biotherapeutics, Inc. (IOVA) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksIOVA deep dive reportAI ChampionsHow we score stocksSense-check another stock